|
Bachurin S, Bukatina E, et al. Antihistamine agent Dimebon as a novel neuroprotector and cognitive enhancer. Annals of the New York Academy of Sciences. 2001;939:425-435.
Bachurin SO, Shevtsova EP, et al. Mitochondria as a target for neurotoxins and neuroprotective agents. Annals of the New York Academy of Sciences. 2003;993:334-344.
Bukatina EE, Afanas’ev AZ, et al. Medicine for treatment of Alzheimer’s disease. Abstract presented at The 4th Congress of the European Society for Clinical Neuropharmacology.
Doody RS, Gavrilova SI, et al. Effect of Dimebon on cognition, activities of daily living, behavior, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled study. The Lancet. 2008;372:207-15.
Grigor’ev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of Dimebon and memantine on AMPA and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bulletin of Experimental Biology and Medicine. 2003;136(5):474-477.
Lermontova NN, Lukoyanov, NV, et al. Dimebon improves learning in animals with experimental Alzheimer’s disease. Bulletin of Experimental Biology and Medicine. 2000;129(6):640-642.
Lermontova NN, Redkozubov AE, et al. Dimebon and tacrine inhibit neurotoxic action of β-amyloid in culture and block L-type Ca2+ channels. Bulletin of Experimental Biology and Medicine. 2001;5:1079-1083.
Marsh JL, Pallos J, et al. Fly models of Huntington’s disease. Human Molecular Genetics 2003;12:R187-R193.
Marsh JL, Thompson LM. Can flies help humans treat neurodegenerative diseases. BioEssays 2004;26:485-496.
Tariot P, Farlow, M, et al. Memantine treatment in patients with moderate to severe Alzheimer’s disease already receiving donepezil. JAMA 2004;291(3):317-324.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004;10(1):33-39.
|
